Comparing biomarkers as trial level general surrogates-Reference-Cited by-同舟云学术

Comparing biomarkers as trial level general surrogates

Published:2016-04 Issue:4 Volume:72 Page:1046-1054
ISSN:0006-341X
Container-title:Biometrics
language:en
Short-container-title:Biom

Author:

Gabriel Erin E.¹,Daniels Michael J.²³,Halloran M. Elizabeth⁴⁵⁶

Affiliation:

1. Biostatistics Research Branch, Division of Clinical Research, NIAID/NIH Bethesda, Maryland, U.S.A.

2. Department of Statistics and Data Sciences, The University of Texas at Austin U.S.A.

3. Department of Integrative Biology, The University of Texas at Austin U.S.A.

4. Department of Biostatistics, School of Public Health, University of Washington Seattle, Washington, U.S.A.

5. Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center Seattle, Washington, U.S.A

6. Center for Inference and Dynamics of Infectious Diseases Seattle, Washington, U.S.A.

Publisher

Wiley

Subject

Applied Mathematics,General Agricultural and Biological Sciences,General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine,Statistics and Probability

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/biom.12513

Reference24 articles.

1. On the relationship between the causal-inference and meta-analytic paradigms for the validation of surrogate endpoints

2. Immunogenicity of the pentavalent rotavirus vaccine in African infants

3. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial

4. A simple meta-analytic approach for using a binary surrogate endpoint to predict the effect of intervention on true endpoint

5. Validation of surrogate end points in multiple randomized clinical trials with failure time end points

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Four statistical frameworks for assessing an immune correlate of protection (surrogate endpoint) from a randomized, controlled, vaccine efficacy trial;Vaccine;2024-04

2. Flexible evaluation of surrogate markers with Bayesian model averaging;Statistics in Medicine;2023-12-11

3. Flexible evaluation of surrogacy in platform studies;Biostatistics;2023-01-04

4. Correlates of Protection;Plotkin's Vaccines;2023

5. An alternative trial-level measure for evaluating failure-time surrogate endpoints based on prediction error;Contemporary Clinical Trials Communications;2019-09